-
What is iMedicus?
iMedicus is Canada’s most innovative livestream CME channel for specialists and family physicians!
Diabetes Update 2024
SAVE THE DATE for the 11th edition of Diabetes Update !
Watch Now!
Hyperkalemia management in Heart Failure - Watch Now!
Obesity Update 2024
JOIN US for the 1st edition of Obesity Update that will serve as a prelude to the esteemed 11th annual Diabetes Update
Arrhythmia Update 2024
Arrhythmia Update 2024 - Register Now!
The New HFrontier: Watch Now!
The New HFrontier: Worsening Heart Failure
upcoming
featured
11:26
Diabetes Update 2022 Podcast Series
Let’s Be Friends: A Collaborative Conversation between Endocrinology and Cardiology
59:51
A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in C
A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in CKD
06:18
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data
06:14
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action
03:14
AIM-LO: Key Tips to Maximize Therapeutic Access for Your Patients
AIM-LO: Key Tips to Maximize Therapeutic Access for Your Patients
04:48
AIM-LO: Engaging With Your Patients about Selection of Injectable Therapies for
Engaging With Your Patients about Selection of Injectable Therapies for LDL-C Reduction
on demand
59:51
A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in C
A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in CKD
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Dosing FAQs
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Dosing FAQs
06:18
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data
06:14
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action
03:14
AIM-LO: Key Tips to Maximize Therapeutic Access for Your Patients
AIM-LO: Key Tips to Maximize Therapeutic Access for Your Patients
04:48
AIM-LO: Engaging With Your Patients about Selection of Injectable Therapies for
Engaging With Your Patients about Selection of Injectable Therapies for LDL-C Reduction
03:14
AIM-LO: Overview of 2021 CCS Dyslipidemia Guidelines: Focus Secondary Prevention
AIM-LO: Overview of 2021 CCS Dyslipidemia Guidelines: Focus on Secondary Prevention
listen now
11:26
Diabetes Update 2022 Podcast Series
Let’s Be Friends: A Collaborative Conversation between Endocrinology and Cardiology
13:33
Diabetes Update 2022 Podcast Series
Incorporating Novel Cardiovascular (Cv) Risk Reduction Strategies for Diabetes Patients: W
